Northwestern Mutual Wealth Management Co. Boosts Stock Position in Insmed, Inc. $INSM

Northwestern Mutual Wealth Management Co. raised its stake in shares of Insmed, Inc. (NASDAQ:INSM) by 8,017.5% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 9,254 shares of the biopharmaceutical company’s stock after acquiring an additional 9,140 shares during the period. Northwestern Mutual Wealth Management Co.’s holdings in Insmed were worth $1,611,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its stake in Insmed by 5.7% during the 4th quarter. Vanguard Group Inc. now owns 21,076,344 shares of the biopharmaceutical company’s stock valued at $3,668,127,000 after acquiring an additional 1,140,524 shares during the last quarter. Darwin Global Management Ltd. raised its stake in Insmed by 5.8% during the 3rd quarter. Darwin Global Management Ltd. now owns 20,457,445 shares of the biopharmaceutical company’s stock valued at $2,897,797,000 after acquiring an additional 1,112,824 shares during the last quarter. Capital International Investors raised its stake in Insmed by 1.0% during the 3rd quarter. Capital International Investors now owns 7,553,853 shares of the biopharmaceutical company’s stock valued at $1,087,830,000 after acquiring an additional 74,994 shares during the last quarter. Artisan Partners Limited Partnership raised its stake in Insmed by 49.0% during the 3rd quarter. Artisan Partners Limited Partnership now owns 4,937,683 shares of the biopharmaceutical company’s stock valued at $711,076,000 after acquiring an additional 1,623,342 shares during the last quarter. Finally, Duquesne Family Office LLC raised its stake in Insmed by 3.0% during the 3rd quarter. Duquesne Family Office LLC now owns 2,423,435 shares of the biopharmaceutical company’s stock valued at $348,999,000 after acquiring an additional 70,000 shares during the last quarter.

Insider Activity at Insmed

In related news, CEO William Lewis sold 10,699 shares of the firm’s stock in a transaction that occurred on Thursday, March 19th. The stock was sold at an average price of $143.52, for a total value of $1,535,520.48. Following the completion of the transaction, the chief executive officer directly owned 301,185 shares of the company’s stock, valued at $43,226,071.20. This trade represents a 3.43% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Roger Adsett sold 88,060 shares of the firm’s stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $164.63, for a total value of $14,497,317.80. Following the completion of the transaction, the chief operating officer directly owned 106,810 shares of the company’s stock, valued at $17,584,130.30. The trade was a 45.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 156,643 shares of company stock valued at $24,513,766 in the last ninety days. Corporate insiders own 2.10% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have commented on the company. Truist Financial reduced their price objective on Insmed from $205.00 to $185.00 and set a “buy” rating for the company in a research note on Wednesday, May 13th. Raymond James Financial assumed coverage on Insmed in a research note on Friday, April 10th. They set an “outperform” rating and a $200.00 target price for the company. Mizuho increased their target price on Insmed from $204.00 to $206.00 and gave the stock an “outperform” rating in a research note on Wednesday, March 25th. HC Wainwright reissued a “buy” rating on shares of Insmed in a research note on Friday, May 8th. Finally, Leerink Partners increased their target price on Insmed from $210.00 to $215.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 24th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $210.95.

Insmed Stock Performance

Shares of INSM stock opened at $106.40 on Thursday. The company has a market cap of $23.06 billion, a price-to-earnings ratio of -18.50 and a beta of 0.89. The stock has a 50 day simple moving average of $135.85 and a 200-day simple moving average of $159.04. Insmed, Inc. has a 12-month low of $65.56 and a 12-month high of $212.75. The company has a current ratio of 4.47, a quick ratio of 4.10 and a debt-to-equity ratio of 0.80.

Insmed (NASDAQ:INSM) last released its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, beating the consensus estimate of ($0.90) by $0.14. Insmed had a negative return on equity of 130.11% and a negative net margin of 144.44%.The firm had revenue of $305.96 million during the quarter, compared to the consensus estimate of $300.81 million. During the same period last year, the business posted ($1.42) EPS. Insmed’s quarterly revenue was up 229.7% on a year-over-year basis. On average, equities analysts forecast that Insmed, Inc. will post -2.52 EPS for the current year.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.